Drug intelligence / Profile preview

DWP DE-2503

Development stage: Unknown
Lead developer: Daewoo Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

DWP DE-2503 is an investigational ophthalmic drug candidate being developed by Daewoo Pharma for the treatment of glaucoma. As of early 2024, the project is in Phase 1 clinical development. While specific pharmacological details, such as its molecular target or mechanism of action, have not been publicly disclosed by the developer, it is part of a robust pipeline of ophthalmic treatments at Daewoo Pharma. The drug is likely being developed as a topical formulation aimed at reducing intraocular pressure, a standard therapeutic approach for managing glaucoma progression.

Beyond the preview

Go deeper on DWP DE-2503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP DE-2503.

Explore the full profile